Tag: Weight Loss
Continuing Tirzepatide Leads to Maintenance of Weight Reduction
Continued tirzepatide treatment maintains and augments initial weight reduction seen in first 36 weeks
Slow-to-Moderate Weight Loss Linked to Lower Mortality in Knee, Hip OA
Weight loss has dose-response protective effect on incident hypertension, type 2 diabetes, venous thromboembolism
Eli Lilly Says Its New Weight-Loss Drug, Zepbound, Is Now Available
Tirzepatide, the active ingredient in Zepbound, had already been approved by the FDA as a treatment for type 2 diabetes
AHA: Semaglutide Cuts Risk for CVD Events in Patients Without Diabetes
Findings seen over three years in adults with preexisting cardiovascular disease and overweight or obesity
FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro
Zepbound works by activating hormone receptors in the body to reduce appetite and food intake
Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention
Authors say additional benefits seen for other health-related measures
FDA Investigating Hospitalizations Linked to Counterfeit Ozempic
Novo Nordisk has said that it is working with the FDA to make consumers aware of the counterfeits
Presenting Weight Loss Treatment as Positive Opportunity Is Beneficial
Uptake of treatment and weight change greater when referral is presented as good news relative to neutral news
Time-Restricted Eating Effective for Weight Loss, Lowering HbA1c
TRE without calorie counting is effective and yields significant reduction in body weight at six months
Weight Loss-Driven Remission of Prediabetes Tied to Lower Type 2 Diabetes Risk
Those reversing prediabetes show improvement in insulin sensitivity but not greater weight loss than those not achieving remission
